课题基金 / 基金详情

Ursolic acid: a novel oral therapy for chronic stage of MS/EAE by both immunomodulation and neural repair

Ursolic acid: a novel oral therapy for chronic stage of MS/EAE by both immunomodulation and neural repair
熊果酸:一种通过免疫调节和神经修复治疗慢性 MS/EAE 的新型口服疗法
批准号:
9384085
负责人:
GUANG-XIAN ZHANG
金额:
$34.13万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-06-01 至 2022-04-30

项目摘要

项目成果

GUANG-XIAN ZHANG的其他基金

相似基金

相关文献

中文摘要
翻译
中枢神经系统(CNS)的炎性脱髓鞘和轴突损伤是其特征 多发性硬化(MS)慢性期及其动物模型--实验性自身免疫 脑脊髓炎(EAE)。目前的多发性硬化症药物主要是免疫调节性的,几乎没有效果。 对受损的中枢神经系统组织的神经再生的影响;因此,它们只在急性时有效,而在 疾病的慢性期。同时具有免疫调节和神经再生作用的多发性硬化症疗法 将是非常有益的。这一目标可以通过使用熊果酸(UA)来实现,熊果酸是一种天然的三萜类化合物 在植物中发现的化合物,广泛存在于人类饮食和抗炎药物中 草药。UA最近被发现可以抑制几种类型的炎症性疾病,并预防EAE 当IP..在发病前注射,通过抑制Th1/Th17细胞分化。UA还保护 神经细胞不会发生凋亡。我们首次证明口服尿酸有效抑制正在进行的EAE 当在急性和慢性EAE阶段开始治疗,并促进大脑中的重新髓鞘形成时- 切片培养。此外,尿酸治疗显著提高核因子IL-3(NFIL3)的表达,a 同时具有免疫调节和神经修复能力的转录因子,缺乏NFIL3 表达在很大程度上减少了UA的影响。 该建议的中心假设是UA是治疗慢性MS/EAE的一种新的口服疗法,谢谢 通过NFIL3诱导的免疫调节和直接神经再生的双重作用 机械装置。为了检验这一假说,本文提出了三个具体目标。从学术的角度来看, 我们有专门的目标1和2来研究UA/NFIL3的作用机制 分别是免疫调节和神经修复。从治疗的角度来看,我们将具体地 目的3检测尿酸对慢性进展期和复发期患者的治疗作用。 汇款(RR)EAE。此外,长期口服尿酸的潜在副作用和安全性问题也将是 受到严密监视。 该项目如果成功,将为UA作为一种口服抗肿瘤药物的巨大潜力提供证据。 炎症和神经修复药治疗MS,特别是在慢性阶段,目前有 没有有效的治疗方法。
英文摘要
Inflammatory demyelination and axonal damage of the central nervous system (CNS) are hallmarks of the chronic stage of multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE). Current MS medications are mainly immunomodulatory, having little or no effect on neuroregeneration of damaged CNS tissue; they are thus only effective in the acute, but not the chronic stage of disease. An MS therapy that has both immunomodulatory and neuroregenerative effects would be highly beneficial. This goal could be achieved by using ursolic acid (UA), a natural triterpenoid compound found in plants that are widely present in the human diet and in anti-inflammatory medicinal herbs. UA has been recently found to inhibit several types of inflammatory diseases and to prevent EAE when i.p. injected before disease onset, by inhibiting Th1/Th17 cell differentiation. UA also protects neurons from apoptosis. We, for the first time, show that oral UA effectively suppresses ongoing EAE when treatment is started at both acute and chronic stages of EAE, and promotes remyelination in brain- slice culture. Further, UA treatment significantly elevates expression of nuclear factor IL-3 (NFIL3), a transcription factor that has both immunomodulatory and neuroreparative capacities, and lack of NFIL3 expression largely reduces UA effects. The central hypothesis of this proposal is that UA is a novel oral therapy for chronic MS/EAE thanks to its dual effects of immunomodulation and direct neuroregeneration, through NFIL3-induced mechanisms. Three specific aims are proposed to test this hypothesis. From the academic perspective, we have dedicated Specific Aims 1 and 2 to investigation of the mechanisms of UA/NFIL3 action in immunomodulation and neural repair, respectively. From the therapeutic perspective, we will in Specific Aim 3 test the therapeutic effects of UA on the chronic stage of chronic-progressive (CP) and relapsing- remitting (RR) EAE. In addition, potential side effects and safety issues of long-term oral UA will also be closely monitored. This project, if successful, will provide evidence that UA has great potential as an oral anti- inflammatory and neural repair agent for MS, especially at the chronic stage, for which there is currently no effective therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ursolic acid: a novel oral therapy for chronic stage of MS/EAE by both immunomodulation and neural repair
  • 批准号:
    9923753
  • 项目类别:
  • 资助金额:
    $34.13万
  • 财政年份:
    2017
  • 负责人:
    GUANG-XIAN ZHANG
  • 依托单位:
NSCs produce a triply effective cocktail in the CNS for MS/EAE therapy
  • 批准号:
    8849995
  • 项目类别:
  • 资助金额:
    $30.52万
  • 财政年份:
    2012
  • 负责人:
    GUANG-XIAN ZHANG
  • 依托单位:
NSCs produce a triply effective cocktail in the CNS for MS/EAE therapy
  • 批准号:
    8545912
  • 项目类别:
  • 资助金额:
    $29.45万
  • 财政年份:
    2012
  • 负责人:
    GUANG-XIAN ZHANG
  • 依托单位:
NSCs produce a triply effective cocktail in the CNS for MS/EAE therapy
  • 批准号:
    8439993
  • 项目类别:
  • 资助金额:
    $30.52万
  • 财政年份:
    2012
  • 负责人:
    GUANG-XIAN ZHANG
  • 依托单位:
海外基金